Full 4th Circuit to Rehear Challenges to State Contract Pharmacy Laws

Why It Matters

The decision could reshape how states regulate 340B contract pharmacies, affecting drug pricing and hospital revenue streams nationwide.

Key Takeaways

• Full 4th Circuit will revisit panel’s unconstitutional ruling
• AHA argues panel invented unsupported preemption theories
• Louisiana and Arkansas courts upheld similar contract‑pharmacy laws
• Outcome may dictate federal‑state balance in 340B program

Pulse Analysis

The 340B Drug Pricing Program, established in 1992, allows eligible hospitals and clinics to purchase outpatient drugs at steep discounts. Over the past decade, many states have expanded the program’s reach through contract‑pharmacy arrangements, letting hospitals dispense discounted medications via third‑party pharmacies. This model has sparked legal disputes over whether state statutes conflict with federal law. The 4th Circuit’s decision to rehear West Virginia and Maryland challenges revives a contentious debate about preemption and the limits of state authority in the 340B landscape.

In April, a three‑judge panel of the 4th Circuit declared the two state laws unconstitutional, citing alleged conflicts with federal statutes. The American Hospital Association, representing hospital interests, slammed the ruling, claiming the majority relied on arguments never raised by the parties and introduced novel preemption theories. The dissent highlighted these flaws, and the AHA’s subsequent amicus briefs underscore the stakes for hospitals that depend on contract pharmacies to extend discounted drug access to patients. Meanwhile, the 5th and 8th Circuits have upheld analogous statutes in Louisiana and Arkansas, creating a split among appellate courts that could prompt Supreme Court review.

The rehearing’s outcome will have far‑reaching implications. Upholding the state laws could solidify a legal foundation for hospitals to expand contract‑pharmacy networks, potentially lowering out‑of‑pocket costs for patients while preserving hospital revenue streams. Conversely, a reversal would reinforce a uniform federal interpretation, limiting state‑level innovations and possibly prompting hospitals to seek alternative cost‑containment strategies. Stakeholders—from health systems to pharmaceutical manufacturers—are watching closely, as the decision will influence pricing dynamics, compliance frameworks, and the broader balance of power between federal drug‑pricing policy and state regulatory initiatives.